Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

NCT05132907 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV2 Infection

Interventions

BIOLOGICAL: HDT-301

Sponsor

HDT Bio

Collaborators

[object Object]
[object Object]